Pharmaceutical composition for treating chloasma

A composition and technology of chloasma, applied in the direction of drug combination, pharmaceutical formula, plant raw materials, etc., can solve the problem that there is no effective treatment drug

Inactive Publication Date: 2016-11-16
JINAN XINGYI MEDICAL TECH
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In terms of drugs, there is no effective treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating chloasma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1: the pharmaceutical composition for the treatment of chloasma and preparation method thereof

[0034] The composition and parts by weight of the crude drug of the pharmaceutical composition for treating chloasma are: 37g of annonaline, 3125g of polyalgae, and 1235g of chrysanthemum;

[0035] Preparation:

[0036] (1) According to the ratio of raw materials, take annonaline, polyalgae, and chrysanthemum, mix well, use ethanol with a concentration of 35% by weight as a solvent, and extract by warm soaking at 25°C. The number of extractions is 0, and each extraction The time is 12 hours, and the amount of solvent used each time is 27 times the total weight of the raw material drug, filtered to obtain medicinal residue A and extract A, the extract A recovers ethanol, concentrates to a relative density of 1.05, filters, and the drug solution passes through FU- 02 macroporous adsorption resin column, elute with water first, then elute FU-02 macroporous adsorptio...

Embodiment 2

[0039] Embodiment 2: the pharmaceutical composition for the treatment of chloasma and preparation method thereof

[0040] The composition and parts by weight of the crude drug of the pharmaceutical composition for treating chloasma are: 36g of annonaline, 3130g of polyalgae, and 1230g of chrysanthemum;

[0041] Preparation:

[0042] (1) According to the ratio of raw materials, take annonaline, polyalgae, and chrysanthemum, mix well, use ethanol with a concentration of 35% by weight as a solvent, and extract by warm soaking at 25°C. The number of extractions is 0, and each extraction The time is 12 hours, and the amount of solvent used each time is 27 times the total weight of the raw material drug, filtered to obtain medicinal residue A and extract A, the extract A recovers ethanol, concentrates to a relative density of 1.05, filters, and the drug solution passes through FU- 02 macroporous adsorption resin column, elute with water first, then elute FU-02 macroporous adsorptio...

Embodiment 3

[0045] Embodiment 3: the pharmaceutical composition for the treatment of chloasma and preparation method thereof

[0046] The composition and parts by weight of the crude drug of the pharmaceutical composition for treating chloasma are: 38g of annonaline, 3120g of polyalgae, and 1240g of chrysanthemum;

[0047] Preparation:

[0048] (1) According to the ratio of raw materials, take annonaline, polyalgae, and chrysanthemum, mix well, use ethanol with a concentration of 35% by weight as a solvent, and extract by warm soaking at 25°C. The number of extractions is 0, and each extraction The time is 12 hours, and the amount of solvent used each time is 27 times the total weight of the raw material drug, filtered to obtain medicinal residue A and extract A, the extract A recovers ethanol, concentrates to a relative density of 1.05, filters, and the drug solution passes through FU- 02 macroporous adsorption resin column, elute with water first, then elute FU-02 macroporous adsorptio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating chloasma and a preparation method thereof. The pharmaceutical composition of the invention is prepared by using ananthine, polyalgae, and chrysanthemum as raw materials, and can be formulated according to conventional preparations. The technology is made into various dosage forms, and the curative effect of treating chloasma is remarkable.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a pharmaceutical composition for treating chloasma and a preparation method thereof. Background technique [0002] Melasma is a hyperpigmented skin disease that is more common in women. The etiology of this disease is not clear, it may be related to the level of estrogen in the body; or there is a linkage genetic pattern with autoimmune thyroid disease, and patients with autoimmune thyroid are prone to chloasma; or it is related to the season, mostly induced after sun exposure in summer Or increase the weight of; long-term use of certain drugs such as chlorpromazine, contraceptives, phenytoin, etc. can also induce this disease. Chloasma belongs to the dark spots in traditional Chinese medicine. Traditional Chinese medicine believes that the disease is closely related to the liver, spleen, and kidneys. The main pathogenesis is that Qi and blood ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/285A61P17/00A61K31/4741
CPCA61K36/185A61K31/4741A61K36/285A61K2236/333A61K2236/39A61K2236/51A61K2236/55
Inventor不公告发明人
OwnerJINAN XINGYI MEDICAL TECH